Catalyst Calendar

Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B

First global approval for Hibsago

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 21, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. (" Azitra " or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has

Notice Regarding Changes in the C-Suite Executive Structure

Roche’s US subsidiary Genentech announces manufacturing expansion in the United States

New facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end U.S. drug manufacturing capabilities. Approximately $750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs....

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 Sol-Gel has initiated a proof-of-concept study in High-frequency BCC (HF-BCC) Sol-Gel initiated a study evaluating topical

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

Adagene to Participate in Three Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

Evaxion announces business update and second quarter 2026 financial results

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

CARLSBAD, Calif. --(BUSINESS WIRE)--Aug. 20, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31 in Munich.

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in novel-novel combination treatment strategies Updated overall survival data for

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 19, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share.

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance 1: Double-digit revenue growth and gross margin

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr.

Telix HY26 Results Presentation

Telix HY26 Results Announcement

Telix HY26 Appendix 4D and Interim Report

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of care associated with GSDIa Ultragenyx received a Priority Review Voucher upon approval Ultragenyx to host conference call on

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026 Morgan Stanley 24 th Annual Global Healthcare Conference at

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company’s Chief Commercial

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Reports Second Quarter 2026 Financials

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from the OPTIMA trial demonstrating a 90% or greater reduction in new HO lesions at

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC PRINCETON, N.J., CAMBRIDGE, Mass., August 19, 2026 — Taiho Oncology, Inc.

NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage System

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary analysis demonstrates preservation of the critical disulfide bond architecture

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D....

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes – – Publication provides peer-reviewed validation for V007 Phase 3 data, and complements recent release of Phase 3 V012 data showing ATEV outperformed

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran...

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

Director/PDMR Shareholding

19 August 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 17 August 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to the Company's Chief Financial Officer, Dr Aradhana Sarin, under the AstraZeneca Performance Share Plan (the AZPSP)....

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

Basel, August 19, 2026 – Novartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress, reinforcing its leadership in addressing cardiovascular risk....

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program SARASOTA, FLA., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company&#x...

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 18, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at

Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome payload-specific resistance Results strengthen the rationale for a differentiated

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens Entera’s clinical execution team and late-stage development capabilities ahead of planned EB613

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel – – Symvess is available off-the-shelf in the operating room, sparing surgeons the time required to harvest a